Novel Deep Brain Simulation Approach for Treating Drug-Refractory Epilepsy Mar. 6, 2023 — A research team proposes an innovative sequential narrow-field deep brain stimulation procedure to treat ...

Managing epilepsy is more than managing seizures. Explore resources that address independent living and quality of life. How Can Epilepsy Impact Your Lifestyle and Independence? Many aspects of ...

Last month, a second phase 3 blow for Marinus Pharmaceuticals prompted the Pennsylvania-based drugmaker to turn an eye toward ...

Longboard Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has initiated its ...

The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based ...

All patients with “de novo” SE were followed up to identify the possible development of post-SE symptomatic epilepsy. Results: A total of 83 episodes fulfilled our criteria of SE. Of these 43% were ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Good afternoon, and thank you for standing by. At this time, I’d ...

Biotech industry leaders added to the Board of Directors, bringing deep expertise in drug discovery, neuroscience clinical development, and ...

The following story was written by Ozzie, a recent Children's Hospital Colorado Junior Reporter.

Rates of survival after out-of-hospital cardiac arrest (OHCA) have not fully bounced back since the COVID-19 pandemic, ...

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and ...